Skip to main content
Contact Us
Back to Homepage
follow us on linkedin
follow us on facebook
follow us on twitter
Investors
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
Site Search
toggle main menu
News
Investors
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
Normal
Press release year list
2021
2020
2019
2018
2017
2016
2015
2014
04/12/2021
Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
04/12/2021
Marinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments
Download
PDF format download (opens in new window)
03/24/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
03/24/2021
Marinus Pharmaceuticals Appoints Dr. Saraswathy (Sara) Nochur to Board of Directors
Download
PDF format download (opens in new window)
03/09/2021
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results
Download
PDF format download (opens in new window)
02/23/2021
Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization
Download
PDF format download (opens in new window)
02/17/2021
Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences
Download
PDF format download (opens in new window)
02/12/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
02/10/2021
Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
Download
PDF format download (opens in new window)
01/26/2021
Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus
Download
PDF format download (opens in new window)
01/13/2021
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)
Download
PDF format download (opens in new window)
01/06/2021
Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference
Download
PDF format download (opens in new window)